Compound Advantage

The DuraSite^® technology platform can be customized to deliver a wide variety of potential drug candidates. As demonstrated in the formulation of AzaSite^®, this powerful drug delivery technology offers a number of benefits for potential ocular drug candidates that are attractive to physicians and patients alike:

• Known safety profile
• Compatible with small molecules to high molecular weight proteins
• Improved residence time in the tear film
• Improved absorption by the conjunctiva and cornea
• Dramatically reduced dosing schedule with potential once-a-day dosing
• Improved patient compliance

For information about DuraSite technology licensing and partnership opportunities, contact David Heniges at DHeniges@insite.com.